Vistagen Therapeutics, Inc.
VTGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001411685
No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Vistagen Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 58 | 1 | 55 | −2 |
| Shares | 23.4M | 44.0K | 13.8M | −9.57M (−41.0%) |
| Value | $81.8M | $156.0K | $8.84M | −$72.8M (−89.2%) |
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (14)
Institutions that held Vistagen Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Luminus Management LLC | 350,000 | $231.7K | 0.21% |
| Omers Administration Corp | 103,400 | $68.4K | 0.00% |
| Tudor Investment Corp Et Al | 76,172 | $50.4K | 0.00% |
| Seven Fleet Capital Management LP | 62,701 | $41.5K | 0.03% |
| Qube Research & Technologies Ltd | 60,139 | $39.8K | 0.00% |
| Virtu Financial LLC | 37,739 | $25.0K | 0.00% |
| HRT Financial LP | 37,585 | $24.0K | 0.00% |
| Engineers Gate Manager LP | 30,490 | $20.2K | 0.00% |
| Lighthouse Investment Partners, LLC | 20,580 | $13.6K | 0.00% |
| Marshall Wace, LLP | 19,973 | $13.2K | 0.00% |
| Caption Management, LLC | 16,770 | $11.1K | 0.00% |
| StoneX Group Inc. | 13,349 | $8.84K | 0.00% |
| DRW Securities, LLC | 10,000 | $6.62K | 0.00% |
| Tower Research Capital LLC (TRC) | 8,564 | $5.67K | 0.00% |
Sold out (16)
Institutions that held Vistagen Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Janus Henderson Group PLC | 4,165,767 | $14.7M |
| Nantahala Capital Management, LLC | 1,978,492 | $7.02M |
| Commodore Capital LP | 1,575,000 | $5.59M |
| Soleus Capital Management, L.P. | 550,000 | $1.95M |
| Almitas Capital LLC | 261,399 | $928.0K |
| BML Capital Management, LLC | 150,000 | $532.5K |
| Citadel Advisors LLC | 122,062 | $433.3K |
| XTX Topco Ltd | 69,712 | $247.5K |
| Walleye Capital LLC | 67,770 | $240.6K |
| Goldman Sachs Group Inc | 60,152 | $213.5K |
| Gsa Capital Partners LLP | 31,486 | $112.0K |
| Quadrature Capital Ltd | 15,752 | $55.8K |
| Blair William & Co | 12,573 | $44.6K |
| FNY Investment Advisers, LLC | 6,000 | $21.0K |
| Citigroup Inc | 3,453 | $12.3K |
| Barclays PLC | 1 | $4 |
Not filed for Q4 2025 yet (1)
Institutions that held Vistagen Therapeutics, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Cubist Systematic Strategies, LLC | 43,953 | $156.0K |